Rabbit viral haemorrhagic virus capsid protein gene recombination adenovirus and bacterin

Abstract

The invention relates to recombinant adenovirus of capsid protein gene of rabbit viral hemorrhagic disease viruses and vaccines, which belong to the bio-pharmaceutical field. A capsid protein VP60 whole gene of the rabbit viral hemorrhagic disease viruses is amplified through RT-PCR, an adenovirus recombinant vector is constructed through the molecular biotechnology, HEK293-A cells are transfected, which enables the VP60 gene to obtain expression, and then gene engineering vaccines of the rabbit viral hemorrhagic disease are prepared through taking the capsid protein VP60 of the rabbit viral hemorrhagic disease viruses of the recombinant adenovirus expression as antigen and adding corresponding adjuvant. The invention can provide the capsid protein gene engineering vaccines of the rabbit viral hemorrhagic disease with good immune effects and simple technology, which is used for preventing and controlling the rabbit viral hemorrhagic disease.

Description

technical field [0001] The invention relates to a recombinant adenovirus and a vaccine of rabbit viral hemorrhagic disease virus capsid protein gene, belonging to the field of biopharmaceuticals. Background technique [0002] Rabbit viral hemorrhagic disease, also known as rabbit plague, is a rabbit infectious disease characterized by acute, highly contagious, and large-scale death caused by rabbit viral hemorrhagic disease virus (RHDV). Infected rabbits usually die within 48 to 72 hours , the main features are highly infectious, respiratory system hemorrhage, liver necrosis, visceral edema, congestion and hemorrhage and other changes, which have caused huge economic losses to the rabbit industry all over the world. The International Veterinary Bureau listed the disease as a Class B infectious disease, and the No. 96 Order of the Ministry of Agriculture of my country promulgated it as a Class II disease. The emergence of RHD is relatively sudden and the epidemic speed is ex...

AI Technical Summary

Problems solved by technology

In recent years, with the rise of industries such as rabbit products and the increase in demand for rabbits such as other animal vaccines, the market demand for rabbit viral hemorrhagic disease vaccines has increased a lot, but non-immune vaccines used to prepare tissue inactivated vaccines The supply of rabbits is very unstable, which causes the cost of traditional tissue-inactivated vaccines to increase continuously. In addition, tissue-inactivated vaccines have various disadvantages such as the potential risk of spreading virulence. However, RHDV has not been successfully passed on cells so far, which seriously restricts The development and production of a safer and more stable rabbit viral hemorrhagic disease vaccine has turned people's research on rabbit viral hemorrhagic disease vaccine to the development of a genetically engineered vaccine that can not only play a protective role, but also solve biological safety problems.

Images